Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195213 | 1.00 | CCR2 (0.46) | CCR2MAPK1MEP1BKMT2ATDP1 | |
| SCHEMBL12418342 | 0.82 | PIK3CD (0.47) | MAPK1SMN1; SMN2KDM4ERECQLTP53 | |
| SCHEMBL2192902 | 0.80 | IDH2 (0.53) | — | |
| SCHEMBL2192909 | 0.80 | IDH2 (0.53) | — | |
| SCHEMBL19156646 | 0.78 | IDH2 (0.53) | KMT2ATDP1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL19156598 | 0.78 | IDH2 (0.53) | KMT2ATDP1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL4799245 | 0.77 | KDM4E (0.53) | MAPK1KMT2ATDP1SMN1; SMN2KDM4E | |
| SCHEMBL4799253 | 0.77 | KDM4E (0.53) | MAPK1KMT2ATDP1SMN1; SMN2KDM4E | |
| SCHEMBL28022848 | 0.76 | PDK1 (0.42) | — | |
| SCHEMBL1723334 | 0.76 | DPP4 (0.56) | SMN1; SMN2KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9302984-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-9050329-B1 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8822507-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (US) | 2013-09-19 | — | — | US | disclosed |
| US-8435968-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | CCR2 19/4885MAPK1 1950/4885MEP1B 3703/4885 |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | CCR2 18/4885MAPK1 1918/4885MEP1B 3687/4885 |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | CCR2 18/4885MAPK1 1918/4885MEP1B 3687/4885 |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | CCR2 18/4885MAPK1 1918/4885MEP1B 3687/4885 |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | CCR2 18/4885MAPK1 1918/4885MEP1B 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.